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ARTICLE
Prediction of Clinical Transporter-Mediated Drug–Drug 
Interactions via Comeasurement of Pitavastatin and 
Eltrombopag in Human Hepatocyte Models
Simon J. Carter1, Bhavik Chouhan2, Pradeep Sharma3 and Michael J. Chappell1,* 
A structurally identifiable micro-rate constant mechanistic model was used to describe the interaction between pitavastatin 
and eltrombopag, with improved goodness-of-fit values through comeasurement of pitavastatin and eltrombopag. Transporter 
association and dissociation rate constants and passive rates out of the cell were similar between pitavastatin and eltrom-
bopag. Translocation into the cell through transporter-mediated uptake was six times greater for pitavastatin, leading to 
pronounced inhibition of pitavastatin uptake by eltrombopag. The passive rate into the cell was 91 times smaller for pitavas-
tatin compared with eltrombopag. A semimechanistic physiologically-based pharmacokinetic (PBPK) model was developed 
to evaluate the potential for clinical drug–drug interactions (DDIs). The PBPK model predicted a twofold increase in the pita-
vastatin peak blood concentration and area under the concentration-time curve in the presence of eltrombopag in simulated 
healthy volunteers. The use of structural identifiability supporting experimental design combined with robust micro-rate con-
stant parameter estimates and a semimechanistic PBPK model gave more informed predictions of transporter-mediated DDIs.
Pitavastatin, one of the family of 3-hydroxy-3-methyl-glu-
taryl-CoA (HMG-CoA) reductase inhibitors used to manage 
hypercholesterolemia, has been determined in vitro to be a 
substrate of organic anion transporting polypeptide (OATP)1B1 
and OATP1B3 (fraction transported of 0.78) and of the efflux 
transporters breast cancer resistance protein (BCRP) and mul-
tidrug resistance associated protein (MRP) 2.1,2 Pitavastatin 
is more sensitive to transporter inhibition than rosuvastatin 
in vitro as well as in healthy volunteers2 and is therefore a 
good candidate for evaluating transporter-mediated drug–
drug interactions (TrDDIs). Elimination of pitavastatin through 
metabolism and urinary excretion is relatively small compared 
with the biliary elimination of pitavastatin (53%).3
Eltrombopag is a thrombopoietin agonist used in the 
management of thrombocytopenic purpura, and the dose is 
individualized based on the platelet count to prevent exces-
sive clotting or a lack of effect.4 It is highly protein bound, 
and the adsorption to plasma proteins was included to 
obtain an inhibition concentration at half of the maximum 
inhibition (IC50) value that explained the inhibition of rosuvas-
tatin.5 In vitro studies found eltrombopag to be a substrate 
of OATP1B1, OATP2B1, organic cation transporter 1 (OCT1), 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔   Currently, most in vitro models are not guided by 
structural identifiability analysis, relying on substrate-only 
measurements to evaluate transporter inhibition and sub-
sequent drug–drug interaction (DDI) predictions.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔   Whether using micro-rate constants compared with 
macro-rate constants to describe the comeasurement of up-
take of substrate (pitavastatin) and inhibitor (eltrombopag) can 
improve model fits through structurally identifiable mechanis-
tic models, and the potential for transporter DDIs in the clinic.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔   The comeasurement of pitavastatin and eltrombopag 
guided structurally identifiability analysis and improved 
model fits through micro-rate constants compared with 
macro-rate constants in human hepatocytes, with addi-
tional information provided regarding transporter binding. 
The parameter estimates were then scaled to a semi-
mechanistic physiologically-based pharmacokinetics 
(PBPK) model to predict potential clinical interactions.
HOW MIGHT THIS CHANGE DRUG DISCOVERY, DE-
VELOPMENT, AND/OR THERAPEUTICS?
✔  Micro-rate constants provide a more dynamic view 
of binding and translocation, furthering the understand-
ing of transporter pharmacology compared with macro-
rate constants, which can be used in the development of 
PBPK models and thereby decrease the risk for clinical 
transporter-mediated DDIs.
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and BCRP and is also able to inhibit probe substrates for 
each transporter.5,6 The uptake by OATP1B1 is disputed 
perhaps because of the large amount of nonspecific binding 
to plastic.4,6
Structural identifiability analysis considers the unique-
ness of the unknown model parameters from the proposed 
input–output model structure corresponding to the proposed 
data collection used for parameter estimation.7-10 This is 
an important, but often overlooked, theoretical prerequisite 
to experiment design and parameter estimation because 
estimates for unidentifiable parameters are effectively 
meaningless. It is therefore important from a systems phar-
macology approach to evaluate, assuming noise-free data, 
whether the proposed mathematical model is at least struc-
turally locally identifiable.7-10 Evaluation of TrDDIs in vitro is 
normally conducted without the comeasurement of both 
substrate and inhibitor in the same sample, assuming that 
the inhibitor is equal in the medium and cellular compart-
ments using Michaelis-Menten kinetics. This can lead to the 
structural unidentifiability of the model, affecting the robust-
ness of estimated parameters, upon which critical decisions 
may be based.7 However, unlike the use of Michaelis-Menten 
kinetics, the structural identifiability of micro-rate constant 
mechanistic models are unaffected by this assumption.11,12
Clinical drug–drug interactions (DDIs) have been observed 
between eltrombopag and rosuvastatin (as a perpetrator13) 
and lopinavir–ritonavir (as a victim14). The main cause of 
the interaction of eltrombopag with rosuvastatin in vitro 
was the result of BCRP inhibition, with minimal inhibition 
of OATP1B1.5,15 This was confirmed in a semimechanistic 
physiologically-based pharmacokinetic (PBPK) model com-
prising the gastrointestinal tract, liver extracellular space, 
liver, and a central compartment to adequately describe the 
interaction between rosuvastatin and eltrombopag.5
The aim of this article is to describe the TrDDI between 
pitavastatin (substrate) and eltrombopag (inhibitor) using 
an in vitro micro-rate constant mechanistic modeling ap-
proach. The micro-rate constants were used to describe 
the dynamic transporter interactions following the comea-
surement of both in cryopreserved human hepatocytes. 
The obtained parameters from the in vitro experiment 
were then scaled to a semimechanistic PBPK model to 
evaluate the interaction between pitavastatin and eltrom-
bopag in simulated healthy volunteers and compared with 
a static model used to predict clinical interactions (R 




Eltrombopag and pitavastatin calcium were obtained from 
Toronto Research Chemicals (Toronto, Ontario, Canada), ce-
sium chloride (C3032), mineral oil (69794, density 0.872 g/L), 
oil red O (O0625), dimethyl sulfoxide (DMSO, ≥99.5%), 
formic acid (99%) and 5,5-diethyl-1,3-diphenyl-2-iminobar-
bituric acid (S518891) were obtained from Sigma-Aldrich 
(Stockholm, Sweden). Acetonitrile, methanol, Leibovitz L15 
(21083027), and silicone oil (15445005, density 1.08  g/L) 
were of analytical or cell culture grade and obtained from 
Thermo-Fisher Scientific Inc. (Gothenburg, Sweden).
Use of hepatocytes
Human hepatocytes were obtained from BioIVT (Brussels, 
Belgium; lot number: LYB; 10 donor LiverPool (8 Caucasians, 
1 African American, and 1 Hispanic) and thawed according 
to supplier guidelines in Leibovitz L15 medium. Hepatocytes 
were kept on ice prior to use and were used within 3 hours 
of defrosting.
Incubations
Hepatocytes (viability 84–87%) were preincubated in Leibovitz 
L15 medium at 1.5 × 106 cells for 15 minutes at 37ºC with ei-
ther 0.1% DMSO or 45  nmol/mL eltrombopag. Incubations 
were started by the addition of pitavastatin (0.3–100  nmol/
mL, 1 × 106 cells, 0.35% DMSO, 30 nmol/mL eltrombopag 
final), and 100 µL samples taken at 0.25–30 minutes. Cells 
were separated using an oil spin method similar to the litera-
ture.11,17 After separation, the tubes were frozen on dry ice and 
the bottom layer was cut off. Pitavastatin and eltrombopag 
were extracted in a stop solution prior to ultra-performance 
liquid chromatography–high-resolution mass spectrometry 
analysis (see the Supplemental Material for full experimen-
tal and sample extraction methods).
Data analysis
The bottom layer concentrations of pitavastatin and el-
trombopag were converted to a cellular concentration 




5 cells was 0.3 µL, and the volume of the 
bottom layer of cesium chloride was 15 µL. A dilution fac-
tor of 100 was used to scale from pmol/mL/1 × 105 cells to 
nmol/mL/1 × 106 cells.
Structural identifiability analysis
An efficient computerized method to determine the struc-
tural local identifiability uses the IdentifiabilityAnalysis 
package9,10 in Wolfram Mathematica 11.3 (Wolfram 
Research Inc., Champaign, IL). Given a set of ordinary 
differential equations (ODEs) with an unknown param-
eter vector and known input and a set of measurable 
cellular observations (see Supplemental Material), this 
method gives a Boolean answer to the structural identi-
fiability problem, including the list of any unidentifiable 
parameters.
Mechanistic modeling in hepatocytes
Transporter kinetics are normally evaluated using Michaelis-
Menten kinetics as opposed to through the use of more 
dynamic micro-rate constants11 assuming that:19,20
1.  Association of substrate to transporter (ka.X) is very 
rapid compared with dissociation (kd.X) and thus at 
equilibrium within a short timeframe
2.  The amount of substrate at the transporter is much 
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3. The translocation of substrate from transporter into the 
cell (kt.X) is the rate-limiting step in the transporter-medi-
ated uptake of the substrate
If these assumptions hold, then the Michaelis-Menten 
equation can be derived from the micro-rate constant mod-
els (models 1 and 2, Table  1), defined here as macro-rate 
constant models (models 3 and 4, Table 119,20). To check the 
validity of these assumptions, the micro-rate constant and 
macro-rate constant models with and without the comea-
surement of eltrombopag were evaluated both for competitive 
(models 1 and 3, respectively; Table 1) and noncompetitive 
inhibition (models 2 and 4, respectively; Table 1).
The final chosen mechanistic model (model 1 with the 
comeasurement of pitavastatin and eltrombopag; Table 1) 
was based on the outcome of the structural identifiability 
analysis and goodness-of-fit statistics (Bayesian information 
criterion, and the weighted Bayesian information criterion,21 
and the sum of the relative mean square root error (percent-
age RMSRE); see Supplemental Material). Model 1 was 
described using a set of ODEs representing the following: 
the amount of pitavastatin (X = substrate (S) or pitavasta-
tin (P)) and eltrombopag (X = inhibitor (I) or eltrombopag (E)) 
in the medium (X1), the amount bound to transporter (X2), 
and the intracellular amount (X3). Passive rate constants for 
movement into and out of the cell (kf.X and kbX, respectively) 
as well as uptake transporter-mediated rate constants for 
association to the transporter (kaX) and dissociation (kdX) and 
translocation (ktX) from the transporter into the medium and 
cell, respectively. Metabolism of pitavastatin in the cell was 
through an elimination rate constant (ke). The sets of ODEs 
for all the models (models 1–4; Table 1) tested for structural 
identifiability and used for parameter estimation are included 
in the Supplemental Material.







identifiability (no. of 
parameters  
to be identifiable) BIC (wBIC)
% RMSRE  
(ind pop total)
Competitive Pitavastatin and 
eltrombopag
SI 2652 (1) 7 + 34 = 41
Competitive Pitavastatin SI 1096 (1) 9 + 38 = 47
Noncompetitive Pitavastatin and 
eltrombopag
SI 2681 (0) 7 + 31 = 38
Noncompetitive Pitavastatin SI 1117 (0) 9 + 39 = 48
Competitive Pitavastatin and 
eltrombopag
SI 2871 (0) 13 + 34 = 47
Competitive Pitavastatin U (1: Km.up.P or KI.up.E) 1386 (0) 16 + 42 = 58
Noncompetitive Pitavastatin and 
eltrombopag
SI 2877 (0) 13 + 36 = 49
Noncompetitive Pitavastatin U (1: Vmax.up.P or KI.up.E) 1378 (0) 16 + 46 = 62
Dotted arrows =comeasurement of eltrombopag. Bold font indicates the best-fitting model based on the percentage of RMSRE, BIC, and wBIC within the 
same number of timepoints. 
BIC, Bayesian information criterion; ind, individual estimate; KI.up.E, eltrombopag uptake inhibition constant; Km.up.P, pitavastatin amount at half of the maxi-
mum uptake velocity (Vmax.up.P); pop, population estimate; RMSRE, sum of the relative mean square root error; SI, structurally (locally) identifiable; U, uniden-
tifiable; wBIC, weighted Bayesian information criterion.
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Parameter estimation
Parameter estimation was conducted within Monolix 2018 R2 
(Lixoft, Antony, France) for each concentration and experi-
ment as an individual data set, where to ensure positivity, a 
log-normal distribution was assumed for each parameter, 
with a proportional residual error model for the observations. 
Because of the large number of parameters to be estimated 
in the combined pitavastatin and eltrombopag mechanistic 
model, the initial estimates for pitavastatin and eltrombopag 
each were obtained for the micro-rate constant models (no 
macro-rate constant estimates could be obtained for eltrom-
bopag alone for transporter-mediated uptake).
Clinical TrDDI assessment
In vitro evaluation of the potential for clinical TrDDIs are 
important in drug development to decrease the risk of ad-
verse events and improve patient quality of life. The FDA in 
their guidance document for industry16 described the use 
of the static area under the concentration-time curve (AUC) 
difference in the presence and absence of inhibitor (the R 
value1) used to assess the potential for clinical TrDDIs:
where fu.pl is the fraction unbound in the plasma (set to 0.01 
for eltrombopag, the minimum value proposed in the FDA 
draft guidance16 when plasma protein binding ≥ 0.99), KI 
is obtained from the micro-rate constant model (through 
(eltrombopag amount at half of the maximum uptake ve-
locity (Vmax.up.E) (Km.up.E)), Eq. 12 in Table 2) and:
where peak blood concentration (Cmax) is the maximum 
plasma concentration of the inhibitor (nmol/mL), FaFg is the 
fraction absorbed multiplied by the intestinal availability (0.5 
for eltrombopag5), Ka is the absorption rate constant set 
to 0.0084/min for eltrombopag,5 QH is hepatic blood flow 
(Table 2), and Rb is the blood:plasma ratio of 0.78 for eltrom-
bopag.5 An R value ≥ 1.1 indicates that a TrDDI is likely.16
A TrDDI was also assessed using a PBPK model, as-
suming that only the uptake of pitavastatin is inhibited by 
eltrombopag in humans (and vice versa), with no inhibition 
of pitavastatin metabolism (see Figure 1). Pitavastatin is 
metabolized in vitro by both UDP-glucuronosyltransferase 
(UGT)1A3 and 2B7 and cytochrome P450 (CYP)2C9 and 
1B1 and inhibited by eltrombopag (IC50  =  2–20  µM, ex-
ception CYP1B1).4,22 However, the in vitro mechanistic 
models did not support metabolism, and a simulation in-
cluding the inhibition of metabolism of pitavastatin did not 
affect the pitavastatin profile.
The micro-rate constants for transporter-mediated 
uptake and passive uptake were scaled to macro-rate con-
stants (see Table 2) and then empirically scaled up to the 
human body (83 kg, healthy adult;23 see Table 2). The model 
was described using ODEs representing the following: The 
stomach (X1), the gastrointestinal tract (X2), the liver extra-
cellular space (X3), the liver (X4) with biliary clearance into 
the gallbladder (X5) and metabolic clearance as well as a 
central blood or plasma compartment (X6; pitavastatin or 
eltrombopag, respectively), which was linked to X3 via QH. 
See the Supplemental Material for derived ODEs.
The clinical pharmacokinetic data following an oral 1 mg 
pitavastatin dose in healthy volunteers 2 were used to val-
idate the pitavastatin PBPK model. As the PBPK model 
was developed for pitavastatin in the blood, the clinical 
data were converted to blood (ng/mL) by dividing them 
by the blood:plasma ratio obtained from the literature 
(0.42524).
Eltrombopag was assumed only to exist in the plasma, be-
cause of the high level of binding of eltrombopag to plasma 
proteins (99.8%4), and the volume of distribution reported 
for a semimechanistic PBPK model (2940 mL5). Given the 
high level of binding, eltrombopag fraction unbound in the 
plasma values of 0.01,16 0.002,4 and 0.005 were considered, 
with a value of 0.005 giving the best visual fit to the 75 mg 
clinical data for eltrombopag.25 The FaFg for eltrombopag 
was reported as 0.5,5,26 but was assumed to be 1 in the 
PBPK model to better visually fit simulations with the clinical 
eltrombopag data.
The ODE PBPK model (see Figure 1 for schematic and 
Supplemental Material for the set of ODEs) was developed 
using desolve27 in R-studio (v1.1.463, R-Studio Inc., Boston, 
MA) running R-project version 3.6.028 and was similar to that 
used for eltrombopag and rosuvastatin.5 All figures in this ar-
ticle were generated either within Inkscape (0.93, Inkscape.




The micro-rate constant mechanistic models tested (see 
Supplemental Material) were at least structurally locally 
identifiable using the IdentifiabilityAnalysis package,9,10 
with no parameters unknown, as long as the initial amounts 
of drug and outputs (measurement of cellular pitavastatin 
with or without measurement of eltrombopag) were known 
(see Table 1). If the cellular concentrations of pitavastatin 
and eltrombopag were both measured as outputs, then 
the macro-rate constant mechanistic models tested were 
at least structurally locally identifiable with no parameters 
unknown (see Table 1). If only cellular pitavastatin concen-
tration was measured, the macro-rate constant models 
were unidentifiable unless one of the parameters was 
known depending on the inhibition type (see Table 1).
For the PBPK model, assuming known doses of pi-
tavastatin and eltromboag and outputs (measurement of 
pitavastatin and eltrombopag in the central compartment), 
the model was at least structurally locally identifiable with 
no parameters unknown if the following were assumed to be 
known: Volumes and blood flows and the fraction unbound 
in the blood or plasma and tissues.
Mechanistic modeling in hepatocytes
The micro-rate constant mechanistic model with comea-
surement of pitavastatin and eltrombopag and mutual 
competitive inhibition (Table 1, model 1), had a smaller total 
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(41% and 47%, respectively; see Table  1). Neither non-
competitive inhibition of pitavastatin uptake nor any of the 
macro-rate constant models were supported as the best-fit-
ting model (see Table 1) and are not discussed further.
Model 1 (see Table 1 and Figure 1 inset) visually fit the pi-
tavastatin data well (Figure 2, blue lines; Table 1, individual 
RMSRE = 7%), with an initial increase in the cellular pitavas-
tatin concentration at lower incubation concentrations to a 
Table 2 Parameter estimates and scaled estimate physiological values
 Model 1: Micro-rate constant parameter estimates
Parameter Estimates for pitavastatin Estimates for eltrombopag
kaX (/nmol/min) 0.17 (0.14–0.25) 0.26 (0.23–0.31)
kdX (/min) 2.2 (1.97–2.37) 1.57 (1.42–2)
ktX (/min) 1.65 (1.57–1.74) 0.27 (0.24–0.32)
keP (/min) 0.22 (0.2–0.24) NA
To (nmol) 0.18 (0.11−0.37)  
kfX (/min) 5.5 × 10
−4 (4.6 × 10−4–6.1 × 10−4) 0.05 (0.04–0.06)
kbX (/min) 0.21 (0.18–0.22) 0.43 (0.35–0.65)
 PBPK model values (equation or references): drug specific










Vmax.up..X (ng/min/liver) ToktXMWX ⋅HPGL ⋅LWT (6) 3.0 × 10
7 5.1 × 106
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⋅HPGL×LWT ⋅ fhep (10)
CLmet.E =(CL∕F)pl.E ⋅FE ⋅
(
1−Fpl.E
)                     (11)
93
6.8




CLur.P (mL/min) CLpl.P ⋅ fur.P (14) 12 0 parent in urine [
25]
fu.bl.P or pl.E fu.pl.P
Bl:Pl




 (16) 0.026 0.4
b
Vc.X (X6, mL)   5820. Total blood  
volume [23]
2940 [5]
 PBPK model values (reference): physiological values
kbile = 0.062/min






23 QK = kidney blood flow = 1170 mL/min
23
Parameter estimates are the conditional mode of the conditional distribution (minimum-maximum) for 1 × 106 cells.
CL/Fpl.E, estimated CL/F from the plasma for eltrombopag; CLbi.X, biliary clearance of X; CLmet.X, metabolic clearance; CLpl.P, pitavastatin plasma clear-
ance;3 CLur.P, urinary clearance of pitavastatin; FE, approximate eltrombopag bioavailability;
5 ffecal.P and fur.P, fraction of pitavastatin in the feces and urine, 
respectively;3 fhep, fraction of liver that are hepatocytes = 0.6;
43 Fpl..E, fraction of total eltrombopag in the plasma;
5 fu.bl.P, pitavastatin fraction unbound in 
the blood, obtained from the fraction unbound in the plasma (fu.pl.P = 0.004) and the blood:plasma (Bl:Pl) ratio (0.425); fu.L.P, fraction unbound in the liver
42 
(obtained from the RED device conditions where Vinc.RED,incubation volume = 1.203 mL; fu.inc, fraction unbound in the incubation = 0.89; Vmed.RED, 1.2 mL; 
and kmem = approximate membrane volume (1% of cell = 0.00003 mL)); HPGL, hepatocytes per gram liver = 139;
41 Ka.P, first-order absorption rate constant 
for pitavastatin calculated using the mean residence time following oral (PO) and i.v. (IV) administration (MRTP);
22 kaX, kdX, ktX, transporter association, dis-
sociation, and translocation rate, respectively; kbile, bile flow rate; keP, pitavastatin elimination rate constant; kfX and kbX, passive rate constants into and out 
of the cell; kge, inverse of the gastric emptying time = 1/10 minutes;
1 Km.up.X, concentration at half Vmax.up.X; LWT, liver weight for a 83 kg human male; MWX , 
molecular weight of pitavastatin (421.46) or eltrombopag (442); NA, not applicable; Pdif.X and Pdef.X, passive diffusion into and out of the cell, respectively;
18 
PBPK, physiologically-based pharmacokinetic; To, total amount of transporters; Vcell, volume per 1 × 10
6 cells; VC.X, volume of the central compartment 
(blood and plasma for pitavastatin and eltrombopag respectively); Vext.H, volume of liver extravascular space; VGabl, volume of the gall bladder; VL,·liver-
specific gravity = 1695.6 g;23 Vmax.up.X, maximum uptake velocity; Vmed, medium volume per 1 × 10
6 cells = 1 mL; X, pitavastatin (P) or eltrombopag (E).
aVisual fit to tmax.
bVisual fit to data.
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maximum followed by a decrease as a result of loss from 
the cell via metabolism. Pitavastatin uptake was saturated 
as the incubation concentration increased. In the presence 
of eltrombopag, the transporter-mediated uptake of pi-
tavastatin was reduced (Figure  2, red lines), which could 
be overcome by increasing the pitavastatin incubation con-
centration until the fits overlapped the pitavastatin-only 
data (Figure  2, 10–100  nmol/mL). The mechanistic model 
was able to visually recover the eltrombopag concentra-
tions in the presence of pitavastatin, with an initial decrease 
to a new minimum (Figure 3). Because of the variability in 
the measured cellular eltrombopag concentration across 
the three experiments (Figure 3, points), the data are dis-
played after normalization to a 30  nmol/mL incubation of 
eltrombopag alone (Figure  3, “0”). At higher pitavastatin 
incubation concentrations (30 and 100 nmol/mL), the per-
centage of the eltrombopag-only control was lower than 
at lower pitavastatin incubation concentrations. The pas-
sive rate constant into the cell for pitavastatin (kfP) was 380 
times lower than the passive rate constant out of the cell 
(kbP) and 91 times lower than the passive rate constant into 
the cell for eltrombopag (kfE) (see Table 2). The passive rate 
constant out of the cell for eltrombopag (kbE) was twofold 
greater than kbP (see Table 2). Transporter association (ka.X) 
Figure 1 Schematic of the developed semimechanistic physiologically-based pharmacokinetic model for the concentrations in 
the liver compartment (X4) assumed to be involved in the transporter-mediated drug–drug interactions between pitavastatin and 
eltrombopag, which is linked to the concentration in the central compartment (X6) via the concentration in the liver extracellular space 
(X3) through QH. The dose of pitavastatin or eltrombopag are applied as an amount into the stomach (X1), which is then transported 
into the gastrointestinal (GI) tract (X2) and assumed to be in solution, where X = pitavastatin = P or eltrombopag = E. Drug is absorbed 
into X3 where free drug moves into the liver via saturable Michaelis-Menten kinetics. Uptake is inhibited by the opposing drug in X3 via 
the respective uptake concentration at half of the maximum uptake velocity (Km.up.X) shown as the inhibition constant (KI.up). Passive 
movement of drug into and out of the liver is through clearances Pdif.X and Pdef.X, respectively. Both drugs are cleared through biliary 
excretion (CLbi.X) into the gallbladder (X5), and into X2 where they can be reabsorbed. Both drugs have metabolic clearance from the 
liver (CLmet.X) while pitavastatin is also cleared into the urine (CLurine.P) with the kidney blood flow (QK). Inset is the in vitro mechanistic 
model for pitavastatin and eltrombopag representing medium (S1 and I1), transporter (S2 and I2), and within hepatocytes (S3 and I3) 
linked through rate constants obtained during parameter estimation (see Supplemental Material for ODEs), which are then scaled 
accordingly to the whole body (see Eqs. 6–10 in Table 2). kge, gastric emptying rate; kbile, bile flow rate; Ka.X, absorption rate constant 
of X; Inset parameters: ka.X, association rate constant of X; kd.X, dissociation rate constant of X; kt.X, translocation rate constant of X; 
To, total amount of uptake transporter sites; kf.X, passive rate constant for movement of X into the cell from the medium; kb.X, passive 
rate constant for movement of X into the medium from the cell; ke.P, pitavastatin elimination rate constant.
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and dissociation (kd.X) rate constants were similar between 
pitavastatin and eltrombopag (see Table 2). The difference in 
transport between the two substrates was in the transporter 
translocation rate constant (kt.X) where pitavastatin was six-
fold greater than eltrombopag (see Table 2).
For pitavastatin, a fu.inc  =  0.9 (relative standard error 
=  5%) and gave an estimated fu.l.P  =  0.026 (and Table  2) 
with an analytical recovery of 55%. For eltrombopag, the 
fu.inc  =  0.04 (relative standard error =  5%) gave an esti-
mated fu.cell  =  1.2  ×  10
-5 and a low analytical recovery of 
10%, making the estimate unreliable. This was reflected in 
the necessary adjustment of fraction unbound in the liver for 
eltrombopag in the PBPK model (fu.L.E = 0.4; see Table 2).
PBPK model
Although the PBPK models developed here are based 
on the drug characteristics and physiologically based 
simulations of concentration and error, the visual fit for 
a single 1 mg dose of pitavastatin alone (Figure 4a, blue 
lines) followed the data reasonably well (Figure  4a,b, 
Figure 2 Plots of hepatocyte cell concentration against time over 30 minutes for pitavastatin (0.3–100 nmol, blue, normalized to 
t = 15 minutes) with and without 15 minute preincubation with eltrombopag (red). Points are data from three separate experiments. 
Solid lines are the median pitavastatin individual fits with measurement of eltrombopag. Dashed lines are the maximum and minimum 












































Figure 3 Plots of percentages of the maximum eltrombopag only cellular concentration against time over 30 minutes for eltrombopag 
in the presence of pitavastatin (0.3–100 nmol) added at t = 15 minutes (normalized to t = 0 minutes). Shapes are data from three 
separate experiments. Solid lines are the median individual fits from the micro-rate constant model. Subplots are separated by dose 
of pitavastatin and eltrombopag-only control (0).
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solid points and error bars, extracted from literature2). 
The Cmax, time to maximum concentration (tmax), and AUC 
estimates obtained from the PBPK model for pitavastatin 
only were similar to the literature2 (see Table 3). For el-
trombopag alone, the mean simulation following a single 
75 mg dose (Figure 4c, blue lines) visually fitted the litera-
ture plasma concentration25 reasonably well25 and closely 
followed the shape of the plasma concentration vs. time 
data (Figure  4c,d, points, extracted from literature25). 
However, the 5% confidence interval (Figure 4c,d, lower 
dashed lines) increased to large proportions during the el-
trombopag elimination phase, likely as a result of a lack of 
observed elimination of eltrombopag over the hepatocyte 
uptake time course and a high incubation concentration 
of eltrombopag. The Cmax and AUC estimates obtained 
from the PBPK model following a single 75  mg dose of 
eltrombopag were similar to the literature,25 whereas tmax 
was later (see Table 3).
Following a 1 mg dose of pitavastatin and a 75 mg dose 
of eltrombopag, the simulated pitavastatin Cmax in the blood 
increased from 23.1 (12.5–37.0) ng/mL to 47.8 (32.9–66.3) 
ng/mL (Figure 4b, red lines) to above the data for a 2 mg 
dose of pitavastatin (Figure 4b, open circles, extracted from 
ref. 22). No effect was seen in the PBPK model fit for eltrom-
bopag in the plasma following a 75 mg dose and a 1 mg 
dose of pitavastatin (Figure 4d, red lines).
DISCUSSION
In vitro parameters
If kfP is scaled to Pdif.P (Eq. 7 in Table 2), the value was within 
the lower range of the literature (Pdif.P = 0.55 (0.46–0.61) and 
Figure 4 Simulated concentration-time plots following oral pitavastatin (1 mg) and or eltrombopag (75 mg) administration to healthy 
volunteers. Semimechanistic physiologically-based pharmacokinetic (PBPK) model Monte-Carlo simulation fits (100 subjects) 
following a 1 mg pitavastatin dose in the absence (a, blue, solid lines) and presence (b, red, solid lines) of a 75 mg dose of eltrombopag. 
Semimechanistic PBPK model Monte-Carlo simulation fits (100 subjects) following a 75 mg eltrombopag dose in the absence (c, blue) 
and presence (d, red) of a 1 mg dose of pitavastatin. Filled circles and error bars in a and b are the pitavastatin clinical data extracted 
from Prueksaritanont et al.2 (mean ± standard error of the mean, n = 8). Open circles in a and b are the pitavastatin clinical data 
following a 2 mg dose extracted from the US Food and Drug Administration drug submission document.22 Points in c and d are the 
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0.4–13  µL/min/1  ×  106 cells, respectively17,33-35). If kb.P is 
also scaled up to Pdef.P (Eq. 8 in Table 2), the value was sim-
ilar to that obtained with micro-rate constants by Grandjean 
et al.11 (0.62 (0.55-0.67) and 0.89 (27%) µL/min/1 × 106 cells 
respectively) and similar to Pdif.P.
The kaP estimate obtained for pitavastatin in human he-
patocytes over 70 seconds in the literature was more than 
40-fold greater (7.4 (51%)/nmol/min/1 × 106 cells11) than the 
value obtained here (see Table 2), whereas the kdP and ktP 
values were of the same order of magnitude (6.3 and 4.3 
(85%)/min/1  ×  106 cells, respectively,11 and see Table  2). 
The extended time points taken here up to 30 minutes en-
abled the errors in kdP to be determined and reduced the 
error on ktP estimated from the data compared with the lit-
erature.11 If the transporter rate constants are transformed 
to Vmax.up and Km.up (Eqs. 6 and 7, respectively, in Table 2), 
then the difference between pitavastatin and eltrombopag 
can be clearly seen in the Vmax.up. (302 (177–639) and 49 
(28–116) pmol/min/1  ×  106 cells, respectively), and Km.up 
values (22.1 (16.7–25.5) and 7.1 (7.2–9.6) nmol/mL, respec-
tively). The scaled Vmax.up.P value was similar to the literature 
(65–354 pmol/min/1 × 106 cells),11,33,34 whereas Km.up.P was 
10-fold lower than the literature (1.4–2 nmol/mL).11,33,34 
The similar values for Pdif.P and Pdef.P confirm exper-
imentally to that assumed in the literature, i.e., passive 
movement of drug into and out of cell are equal when scaled 
to a clearance.17,33-35 However, this assumption only holds 
when transporter-mediated uptake dominates over passive 
uptake and metabolism, calculated from the fraction trans-
ported (FT.X):
where CLup.X = Vmax.up.X/Km.up.X. For pitavastatin FT.P = 0.96 
(0.94–0.98), uptake clearance dominates over passive, 
whereas for eltrombopag, Pdif.E of 52 (40–64) µL/min/1 × 10
6 
cells dominates compared  with a smaller Pdef.E of 1.3 
(1.05–1.95) µL/min/1 × 106 cells and FT.E = 0.12 (0.09–0.2). 
Eltrombopag was reported to show saturable uptake in 
mouse hepatocytes, attributable to uptake transporters,5 
but only as an inhibitor in the FDA submission document.26 
The transporter-mediated uptake of eltrombopag derived 
using micro-rate constants, which was not possible using 
a macro-rate constant model, agrees with the findings from 
mouse hepatocytes,5 whereas the FT.E value supports the 
FDA submission document26 where passive movement 
dominates.
TrDDI risk assessment
The clinical risk of TrDDI according to the R value2 with el-
trombopag as the perpetrator and pitavastatin as the victim 
was below the FDA cut-off (1.07 at 75 mg). The FDA label 
for eltrombopag states that caution should be taken when 
concomitantly administering eltrombopag with OATP1B1 
substrates.26 The dose of eltrombopag is closely monitored 
in the clinic because of its pharmacological effect,4 and 
the R values were therefore also calculated with eltrom-
bopag as the victim and pitavastatin as the perpetrator. 
No effect of pitavastatin on eltrombopag was seen in the 
experimental data except at a pitavastatin incubation of 
30–100 nmol/mL (see Figure 3). This can also be observed 
with the calculated R value below the cut-offs suggested by 
the FDA.16 This is because of the low dose of pitavastatin 
given (1–4 mg) in the clinic2,36,37 (with an estimated Iin.max 
of 0.5–3 nmol/mL) compared with the estimated pitavasta-
tin KI of 13 (9.5–14) nmol/mL from the micro-rate constant 
model.
The large degree of inhibition by eltrombopag on pitavas-
tatin seen in human hepatocytes (Figure 2, red lines) led to 
the development of a semimechanistic PBPK model (see 
Figure 1) to evaluate the potential for a clinical TrDDI in a 
more dynamic environment. The increase in the simulated 
pitavastatin Cmax in the presence of eltrombopag from 23.1 
(12.5–37.0) ng/mL to 47.8 (32.9–66.5) ng/mL (Table 3) was 
also seen in the AUC R value = 2.4 (2.2–3) in the presence 
and absence of eltrombopag (119 (56–212) and 49 (19–95) 






Table 3 Pharmacokinetic parameter estimates for pitavastatin and eltrombopag in blood and plasma, respectively, obtained from the literature 
and PBPK model simulations
  Cmax tmax (h)
AUC0−t (model) or  
AUC0−∞ (literature)
R value
Static model PBPK model
Pitavastatin only (literature)2a 38.8 ± 21.9 ng/mL 1 (0.5–1) 68 ± 49 h·ng/mL    
Pitavastatin only (PBPK) 23.1 (12.5–37.0) ng/mL 0.97 (0.82–0.95) 49 (19–95) h·ng/mL    
Pitavastatin (PBPK with 
eltrombopag)
47.8 (32.9–66.3) ng/mL 1.2 (1.32) 119 (56–212) h·ng/mL 1.06–1.07 2.4 (2.2–3)
Eltrombopag only (literature)25 10.9 (8.7–13.6) µg/mL 2.5 (2–4) 145 (101–208) h·µg/mL    
Eltrombopag only (PBPK) 10.6 (6.4–15.4) µg/mL 5.2 (5.2–6.8) 338 (118–628) h·µg/mL    
Eltrombopag (PBPK with 
pitavastatin)
10.6 (6.4–15.5) µg/mL 5.2 (0.5–6.8) 339 (118–629) h·µg/mL   1
Values are mean ± standard deviations or mean (95% confidence intervals).
AUC, area under the concentration-time curve; AUC0−t, area under the concentration-time curve to the last timepoint; AUC0−∞, area under the concentration-
time curve to infinity; Cmax, peak concentration; PBPK, physiologically-based pharmacokinetic; tmax, time to peak concentration.
aConverted to blood concentration. R value calculated according to Eq. 216 for static model or the ratio of the AUC in the presence of the inhibitor to the AUC 
in the absence of the inhibitor for the PBPK model simulation.
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calculated R value of 1.06–1.07. The simulated concentra-
tion of eltrombopag in the liver extracellular compartment 
following a 75 mg dose (66,524 ng/mL at 5 minutes) was 
much larger than the KI.E value calculated from the uptake 
experiment (3,138 ng/mL), making a TrDDI more likely with 
pitavastatin as the “victim” drug and eltrombopag as the 
“perpetrator” drug. The inhibition of rosuvastatin by el-
trombopag has been attributed to the inhibition of BCRP 
with little contribution of inhibition of OATP1B1.5,15 For 
the uptake of rosuvastatin to be inhibited to the same ex-
tent that pitavastatin was in this study, the calculated IC50 
had to be 10 times more potent.5 Pitavastatin has been 
shown to be more sensitive to the inhibition of OATP1B1 
compared with rosuvastatin with intravenous rifampicin,2 
and the KI.E estimated here for eltrombopag would there-
fore also be sufficient clinically to inhibit the uptake of 
pitavastatin into the liver, leading to a clinical TrDDI.5,15 The 
Pdif.E value (1.2  ×  10
5  mL/min/liver; Table  2) was much 
greater than the transporter-mediated clearance for eltrom-
bopag (Vmax.up.E.WB/Km.up.E.WB = 1625 mL/min/liver), making 
a TrDDI unlikely with eltrombopag as the “victim” drug and 
pitavastatin as the “perpetrator,” seen from the lack of dif-
ference in the simulated Cmax, tmax, and AUC values (see 
Table  3). The same was concluded for eltrombopag and 
rosuvastatin.5
CONCLUSIONS
By additionally measuring eltrombopag and relying on the 
large amount of uptake data for pitavastatin in human hepato-
cytes in vitro in the presence and absence of eltrombopag, 
robust uptake kinetics for eltrombopag and pitavastatin 
were obtained. The use of a mechanistic modeling approach 
for parameter estimation, guided by structural identifiabil-
ity to improve experimental design, shows the advantage 
of co-measurement of both substrate and inhibitor. An ap-
proach was presented with structural identifiable micro-rate 
constant mechanistic models that can aid in promoting sys-
tems pharmacology models of transporters and allows the 
Michaelis-Menten assumptions for transporters to be formally 
tested. The improvement in the structural identifiability anal-
ysis results and in the model fit seen here using micro-rate 
constants compared with macro-rate constants is in line with 
previous studies,11,12 showing the utility of robust micro-rate 
constant mechanistic models in TrDDI analysis in drug de-
velopment. The developed semimechanistic PBPK model, 
based on the inhibition of uptake into the liver only, predicted 
a likely clinical TrDDI between pitavastatin and eltrombopag 
when compared with use of the static R value.
Future directions
It is recommended to comeasure substrate and inhibitor 
concentrations in the same sample during in vitro TrDDI 
studies, where a comprehensive mechanistic understand-
ing is required. Further work on developing a robust high 
throughput of the uptake method (see refs. 12,38) across 
more structurally diverse substrates and inhibitors will help 
increase confidence on the approach presented here using 
micro-rate constants.
The robust estimation of the parameters for use in the 
PBPK model, rather than the use of fixed parameters (with 
the exception of physiological flows and parameters), and 
the development of a more micro-rate constant-based PBPK 
model may further the adoption of this approach.
Supporting Information. Supplementary information accompa-
nies this paper on the CPT: Pharmacometrics & Systems Pharmacology 
website (www.psp-journal.com).
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